DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
ELISMETREP
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Neuropathies; Hot Flashes
Transient receptor potential cation channel subfamily M member 8 inhibitor
ELISMETREP
×
Maximum Phase:
2
First Approval:
None
UNII:
KIB8V5UR7D
Molecule Type:
Small molecule
Molecular Formula:
C27H21F3N2O5S
Molecular Weight:
542.53
AlogP:
6.1
PSA:
96.8
HBD:
1.0
HBA:
#RotB:
8.0
Source:
PLN-74809
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
PLN-74809
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UBENIMEX
2
Small molecule
Investigational
Unknown
Unknown
Hypertension, Pulmonary; Lymphedema
Unknown
UBENIMEX
×
Maximum Phase:
2
First Approval:
None
UNII:
I0J33N5627
Molecule Type:
Small molecule
Molecular Formula:
C16H24N2O4
Molecular Weight:
308.38
AlogP:
0.53
PSA:
112.65
HBD:
4.0
HBA:
#RotB:
8.0
Source:
FIRTECAN PEGOL
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma; Neoplasms; Breast Neoplasms
Unknown
FIRTECAN PEGOL
×
Maximum Phase:
2
First Approval:
None
UNII:
WC4978T687
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GATAPARSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Leukemia, Myeloid, Acute; Prostatic Neoplasms, Castration-Resistant
Unknown
GATAPARSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
895O8QKF18
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BI-505
2
Antibody
Investigational
Unknown
Unknown
Multiple Myeloma
Intercellular adhesion molecule-1 antagonist
BI-505
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MGB-BP-3
2
Small molecule
Investigational
Unknown
Unknown
Clostridium Infections
DNA binding agent
MGB-BP-3
×
Maximum Phase:
2
First Approval:
None
UNII:
532PWU9738
Molecule Type:
Small molecule
Molecular Formula:
C36H37N7O4
Molecular Weight:
631.74
AlogP:
4.65
PSA:
122.52
HBD:
3.0
HBA:
#RotB:
10.0
Source:
TALAROZOLE
2
Small molecule
Investigational
Unknown
Unknown
Inflammation; Acne Vulgaris; Psoriasis
Cytochrome P450 26A1 inhibitor
TALAROZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
XKD9N5CJ6W
Molecule Type:
Small molecule
Molecular Formula:
C21H23N5S
Molecular Weight:
377.52
AlogP:
5.66
PSA:
55.63
HBD:
1.0
HBA:
#RotB:
7.0
Source:
AVE-1642
2
Antibody
Investigational
Unknown
Unknown
Liver Neoplasms; Multiple Myeloma; Breast Neoplasms
Insulin-like growth factor I receptor antagonist
AVE-1642
×
Maximum Phase:
2
First Approval:
None
UNII:
Z9U2SS9ZC8
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GALICAFTOR
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis
Cystic fibrosis transmembrane conductance regulator positive modulator
GALICAFTOR
×
Maximum Phase:
2
First Approval:
None
UNII:
J0IIT8QSQS
Molecule Type:
Small molecule
Molecular Formula:
C28H21F4NO7
Molecular Weight:
559.47
AlogP:
5.72
PSA:
103.32
HBD:
2.0
HBA:
#RotB:
7.0
Source:
BREQUINAR
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Severe Acute Respiratory Syndrome
Unknown
BREQUINAR
×
Maximum Phase:
2
First Approval:
None
UNII:
5XL19F49H6
Molecule Type:
Small molecule
Molecular Formula:
C23H15F2NO2
Molecular Weight:
375.37
AlogP:
5.85
PSA:
50.19
HBD:
1.0
HBA:
#RotB:
3.0
Source:
TOL-101
2
Antibody
Investigational
Unknown
Unknown
Renal Insufficiency, Chronic
T-cell receptor inhibitor
TOL-101
×
Maximum Phase:
2
First Approval:
None
UNII:
28X0AGG6P8
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
L-THREONIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity
Unknown
L-THREONIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
75B0PMW2JF
Molecule Type:
Small molecule
Molecular Formula:
C4H8O5
Molecular Weight:
136.1
AlogP:
-2.21
PSA:
97.99
HBD:
4.0
HBA:
#RotB:
3.0
Source:
ILODECAKIN
2
Protein
Investigational
Unknown
Unknown
Cicatrix
Unknown
ILODECAKIN
×
Maximum Phase:
2
First Approval:
None
UNII:
6GY6UY4UR7
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FB825
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
FB825
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VX-787
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
VX-787
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MK-0941
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Hexokinase type IV activator
MK-0941
×
Maximum Phase:
2
First Approval:
None
UNII:
YZ1L3KR377
Molecule Type:
Small molecule
Molecular Formula:
C22H28N4O9S2
Molecular Weight:
556.62
AlogP:
2.41
PSA:
132.64
HBD:
2.0
HBA:
#RotB:
9.0
Source:
UK-500001
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase isozyme 4 inhibitor
UK-500001
×
Maximum Phase:
2
First Approval:
None
UNII:
YOG0PR3Q8J
Molecule Type:
Small molecule
Molecular Formula:
C26H24F3N3O4
Molecular Weight:
499.49
AlogP:
4.78
PSA:
100.55
HBD:
3.0
HBA:
#RotB:
6.0
Source:
RIVENPROST
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative
Prostanoid EP4 receptor agonist
RIVENPROST
×
Maximum Phase:
2
First Approval:
None
UNII:
1WBO45T413
Molecule Type:
Small molecule
Molecular Formula:
C24H34O6S
Molecular Weight:
450.6
AlogP:
2.94
PSA:
93.06
HBD:
2.0
HBA:
#RotB:
13.0
Source:
SODIUM CHOLATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
SODIUM CHOLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
NU3Y4CCH8Z
Molecule Type:
Small molecule
Molecular Formula:
C25H41NaO5
Molecular Weight:
444.59
AlogP:
3.84
PSA:
97.99
HBD:
4.0
HBA:
#RotB:
4.0
Source:
AMINOPTERIN
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Endometrial Neoplasms; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psoriasis
Unknown
AMINOPTERIN
×
Maximum Phase:
2
First Approval:
None
UNII:
JYB41CTM2Q
Molecule Type:
Small molecule
Molecular Formula:
C19H20N8O5
Molecular Weight:
440.42
AlogP:
0.24
PSA:
219.33
HBD:
6.0
HBA:
#RotB:
9.0
Source:
552-02
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis
Unknown
552-02
×
Maximum Phase:
2
First Approval:
None
UNII:
81U49K9009
Molecule Type:
Small molecule
Molecular Formula:
C20H30ClN7O7S
Molecular Weight:
548.02
AlogP:
0.09
PSA:
194.99
HBD:
6.0
HBA:
#RotB:
10.0
Source:
RABUSERTIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung
Serine/threonine-protein kinase Chk1 inhibitor
RABUSERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
3S9L1NU6U7
Molecule Type:
Small molecule
Molecular Formula:
C18H22BrN5O3
Molecular Weight:
436.31
AlogP:
2.87
PSA:
97.4
HBD:
3.0
HBA:
#RotB:
5.0
Source:
ORGANON
2
Small molecule
Investigational
Unknown
Unknown
Substance-Related Disorders
Unknown
ORGANON
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C26H35N3O3
Molecular Weight:
437.58
AlogP:
4.78
PSA:
59.49
HBD:
1.0
HBA:
#RotB:
8.0
Source:
GLPG-1205
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative; Idiopathic Pulmonary Fibrosis
G-protein coupled receptor 84 negative allosteric modulator
GLPG-1205
×
Maximum Phase:
2
First Approval:
None
UNII:
K9WR6LRA5D
Molecule Type:
Small molecule
Molecular Formula:
C22H22N2O4
Molecular Weight:
378.43
AlogP:
2.02
PSA:
62.58
HBD:
0.0
HBA:
#RotB:
3.0
Source:
BI 201335 NA
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
BI 201335 NA
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EDRATIDE
2
Protein
Investigational
Unknown
Unknown
Lupus Erythematosus, Systemic
Unknown
EDRATIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
38PLP07BKC
Molecule Type:
Protein
Molecular Formula:
C112H151N27O27
Molecular Weight:
2307.6
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
LACTIN-V
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
LACTIN-V
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RELENOPRIDE
2
Small molecule
Investigational
Unknown
Unknown
Constipation
Unknown
RELENOPRIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
SIS5BFO4WL
Molecule Type:
Small molecule
Molecular Formula:
C24H30ClFN4O4
Molecular Weight:
492.98
AlogP:
3.74
PSA:
119.91
HBD:
3.0
HBA:
#RotB:
9.0
Source:
TISOTUMAB VEDOTIN
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms
Coagulation factor III binding agent
TISOTUMAB VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
T41737F88A
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LENTINAN
2
Unknown
Investigational
Unknown
Unknown
HIV Infections
Unknown
LENTINAN
×
Maximum Phase:
2
First Approval:
None
UNII:
6751655D1D
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FIANLIMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Breast Neoplasms; Hemangiosarcoma
Lymphocyte activation gene 3 protein inhibitor
FIANLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
OX5LRQ5H6K
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PETESICATIB
2
Small molecule
Investigational
Unknown
Unknown
Celiac Disease; Sjogren's Syndrome
Cathepsin S inhibitor
PETESICATIB
×
Maximum Phase:
2
First Approval:
None
UNII:
A26QO95U37
Molecule Type:
Small molecule
Molecular Formula:
C25H23F6N5O4S
Molecular Weight:
603.55
AlogP:
3.36
PSA:
125.16
HBD:
1.0
HBA:
#RotB:
6.0
Source:
ATAGABALIN
2
Small molecule
Investigational
Unknown
Unknown
Sleep Initiation and Maintenance Disorders
Voltage-gated calcium channel modulator
ATAGABALIN
×
Maximum Phase:
2
First Approval:
None
UNII:
JT7957Q2FB
Molecule Type:
Small molecule
Molecular Formula:
C10H19NO2
Molecular Weight:
185.27
AlogP:
1.47
PSA:
63.32
HBD:
2.0
HBA:
#RotB:
3.0
Source:
NESOLICAFTOR
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis
Unknown
NESOLICAFTOR
×
Maximum Phase:
2
First Approval:
None
UNII:
T2U4ZA62U4
Molecule Type:
Small molecule
Molecular Formula:
C18H18N4O4
Molecular Weight:
354.37
AlogP:
2.45
PSA:
114.28
HBD:
2.0
HBA:
#RotB:
5.0
Source:
1
2
…
179
180
181
182
183
184
185
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA